The FDA is expected to decide on treatments for COPD, psoriasis, rare neuroendocrine tumors, and a next-generation COVID-19 vaccine.

A new study published in JCI Insight suggests that interleukin-7 (IL-7), a key immune-boosting cytokine, may help critically ...

This study provides proof-of-principle data for the use of trained immunity to modulate macrophage interactions with tumours. The study makes a valuable contribution to the field of trained immunity.

Shares of Nvidia-backed CoreWeave opened for trading on Friday, raising $1.5B and making it the biggest U.S. tech IPO since 2021, even after ...

Additional data from the MDNA11 ABILITY-1 trial to be presented at the Annual Meeting Pre-clinical data on Medicenna’s first-in-class Masked and Tumor Targeted Bifunctional anti-PD1-IL2 Superkine, ...

four receiving placebo) and 10 patients in Cohort 2 (seven patients in the soquelitinib ... Fas signaling is regulated by ITK and T cell receptor signaling and patients with ALPS have an imbalance in ...

Q4 2024 Earnings Call Transcript March 20, 2025 Monte Rosa Therapeutics, Inc. beats earnings expectations. Reported EPS is $0 ...

Objective Asthma and type 2 diabetes are two important causes of morbidity globally. We examined both the association of type ...

FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large ...

Icotrokinra (JNJ-2113), the first-ever oral IL-23 receptor antagonist developed in collaboration with Johnson & Johnson, which has shown substantial efficacy in multiple Phase 3 trials for psoriasis ...

Body Dimensions 164.5 x 76.2 x 8.1 mm (6.48 x 3.00 x 0.32 in) ...